For informational purposes only — not investment advice

← Back to signals

ACHC

SHORT

ACADIA HEALTHCARE COMPANY IN

Research: Finviz ↗·Perplexity ↗

Funds
3
Score
1.65
vs SPY
-10.8%
Stock return (since Q-end)
-8.7%
SPY return (since Q-end)
+2.1%
Current price
$26.97
Days to cover (short int.)
6.7d↑+0.0%
as of 2026-07-31

News Summary

Negative

Acadia beat Q2 2026 EPS estimates ($0.38 vs. $0.35) and raised full-year revenue guidance to $3.40–$3.45B, but net income fell year-over-year and the stock initially fell 10% despite the beat, signaling investor skepticism. The company faces ongoing government investigations, active securities litigation (with a recent court denial of dismissal motion), and persistent payer negotiation tensions that constrain margin recovery.

Red flags

  • Net income declined year-over-year despite flat revenue
  • Active securities class action lawsuit survived motion to dismiss (August 2026); separate $179M settlement from prior fraud case (2025/2026)
  • Ongoing government investigations with no cost guidance provided
  • Analyst price target of $22.67 implies ~17.8% downside; Jefferies cut target from $34 to $15 in January 2026
  • Market reaction: stock fell 10% immediately after earnings beat, indicating underlying concern about fundamentals
  • Medicaid reimbursement pressures and underperforming locations noted as near-term drag
  • Revenue flat year-over-year (Q2 2026 vs Q2 2025); prior-year benefited from $48.7M one-time Tennessee payments

Funds Reducing / Exiting (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Maverick CapitalLee Ainslie0−1.3M0.4%-100%EXITED
Soros Fund ManagementSoros Family Office0−23K<0.1%-100%EXITED
Point72Steve Cohen0−537K<0.1%-100%EXITED

Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.

Signal History

QuarterDirectionFundsScorevs SPY
Q2 2026SHORT31.65-10.8%
Q1 2026LONG43.63+12.1%

Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
Khrom Investments Fund, LPSC 13G/A647K0.7%2026-08-14
Wellington Management Group LLPSC 13G/A5.7M6.2%2026-08-13
FMR LLCSC 13G/A5.0M5.5%2026-08-06
BlackRock, Inc.SC 13G/A13.8M15.0%2026-07-27
Khrom Investments Fund, LPSC 13G/A5.2M5.7%2026-05-15
Wellington Management Group LLPSC 13G/A9.1M9.9%2026-05-15
THE GOLDMAN SACHS GROUP, INC.SC 13G/A1.5M1.6%2026-05-11
Vanguard Capital ManagementSC 13G4.8M5.3%2026-04-29
Vanguard Portfolio ManagementSC 13G5.1M5.5%2026-04-28

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.